Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)
CUSIP: 89532M101
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 143,562,667
- Total 13F shares
- 130,345,507
- Share change
- +531,201
- Total reported value
- $1,631,941,708
- Put/Call ratio
- 137%
- Price per share
- $12.52
- Number of holders
- 184
- Value change
- +$9,116,093
- Number of buys
- 103
- Number of sells
- 62
Quarterly Holders Quick Answers
What is CUSIP 89532M101?
CUSIP 89532M101 identifies TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 89532M101:
Top shareholders of TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| NEA Management Company, LLC |
13F
|
Company |
9.2%
|
13,222,228
|
$120,983,386 | — | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
7.1%
|
10,259,409
|
$93,873,592 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.6%
from 13D/G
|
9,901,053
|
$90,594,634 | — | 30 Sep 2025 | |
| Rubric Capital Management LP |
13F
13D/G
|
Company |
2.9%
from 13D/G
|
8,531,860
|
$78,066,519 | — | 30 Sep 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
7%
|
8,508,021
|
$77,848,392 | -$16,025,200 | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
5,826,986
|
$53,316,921 | — | 30 Sep 2025 | |
| VIKING GLOBAL INVESTORS LP |
13D/G
13F
|
Company |
4.2%
|
5,128,875
|
$46,929,206 | -$21,747,894 | 30 Sep 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
3.5%
|
5,094,668
|
$46,616,212 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
3.4%
|
4,841,751
|
$44,302,021 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
3%
|
4,301,726
|
$39,360,792 | — | 30 Sep 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
3%
|
4,292,451
|
$39,275,927 | — | 30 Sep 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
2.4%
|
3,406,955
|
$31,173,638 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
2.3%
|
3,308,400
|
$30,271,860 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
2.3%
|
3,299,891
|
$30,194,001 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.3%
|
3,253,888
|
$29,773,074 | — | 30 Sep 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
2%
|
2,815,000
|
$25,757,250 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
2%
|
2,800,000
|
$25,620,000 | — | 30 Sep 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.8%
|
2,536,867
|
$23,212,333 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
2,220,926
|
$20,326,196 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.5%
|
2,219,422
|
$20,307,711 | — | 30 Sep 2025 | |
| Logos Global Management LP |
13F
|
Company |
1.5%
|
2,200,000
|
$20,130,000 | — | 30 Sep 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
1.5%
|
2,144,844
|
$19,625,323 | — | 30 Sep 2025 | |
| Artia Global Partners LP |
13F
|
Company |
1.4%
|
1,999,702
|
$18,297,273 | — | 30 Sep 2025 | |
| Ali Behbahani |
3/4/5
|
10%+ Owner |
8.5%
|
12,273,280
|
$16,814,393 | — | 31 Dec 2025 | |
| Anthony A. Florence Jr. |
3/4/5
|
10%+ Owner |
8.5%
|
12,273,280
|
$16,814,393 | — | 31 Dec 2025 | |
| Carmen Chang |
3/4/5
|
10%+ Owner |
8.5%
|
12,273,280
|
$16,814,393 | — | 31 Dec 2025 | |
| Forest Baskett |
3/4/5
|
10%+ Owner |
8.5%
|
12,273,280
|
$16,814,393 | — | 31 Dec 2025 | |
| Mohamad Makhzoumi |
3/4/5
|
10%+ Owner |
8.5%
|
12,273,280
|
$16,814,393 | — | 31 Dec 2025 | |
| New Enterprise Associates 16, L.P. |
3/4/5
|
10%+ Owner |
8.5%
|
12,273,280
|
$16,814,393 | — | 31 Dec 2025 | |
| Paul Edward Walker |
3/4/5
|
10%+ Owner |
8.5%
|
12,273,280
|
$16,814,393 | — | 31 Dec 2025 | |
| Scott D. Sandell |
3/4/5
|
10%+ Owner |
8.5%
|
12,273,280
|
$16,814,393 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.3%
|
1,836,839
|
$16,807,077 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.1%
|
1,600,742
|
$14,646,789 | — | 30 Sep 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.98%
|
1,411,037
|
$12,910,989 | — | 30 Sep 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.96%
|
1,381,324
|
$12,639,115 | — | 30 Sep 2025 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
0.88%
|
1,256,782
|
$11,499,555 | — | 30 Sep 2025 | |
| FLPUTNAM INVESTMENT MANAGEMENT CO |
13F
|
Company |
0.73%
|
1,048,102
|
$9,590,133 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.66%
|
941,929
|
$8,618,650 | — | 30 Sep 2025 | |
| Venrock Healthcare Capital Partners II, L.P. |
13D/G
|
— |
1.4%
|
1,266,457
|
$8,042,002 | $0 | 31 Dec 2024 | |
| TPG GP A, LLC |
3/4/5
|
Former 10% Owner |
—
class O/S missing
|
3,824,883
|
$7,726,264 | — | 01 Jul 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.56%
|
806,331
|
$7,377,929 | — | 30 Sep 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
0.55%
|
792,806
|
$7,254,175 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.55%
|
787,454
|
$7,205,204 | — | 30 Sep 2025 | |
| Rosalind Advisors, Inc. |
13D/G
13F
|
Company |
1.2%
|
1,062,500
|
$6,746,875 | $0 | 13 Feb 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
736,930
|
$6,742,910 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.51%
|
727,596
|
$6,657,503 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.45%
|
651,679
|
$5,962,863 | — | 30 Sep 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.45%
|
643,957
|
$5,892,207 | — | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.44%
|
626,462
|
$5,732,127 | — | 30 Sep 2025 | |
| PEREGRINE CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.43%
|
620,464
|
$5,677,246 | — | 30 Sep 2025 |
Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q4 2025
As of 31 Dec 2025,
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) was held by
184 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
130,345,507 shares.
The largest 10 holders included
NEA Management Company, LLC, Frazier Life Sciences Management, L.P., BlackRock, Inc., FMR LLC, VANGUARD GROUP INC, Vivo Capital, LLC, MARSHALL WACE, LLP, Rubric Capital Management LP, WELLINGTON MANAGEMENT GROUP LLP, and MPM BIOIMPACT LLC.
This page lists
184
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
163
Q4 2025 holders
184
Holder diff
21
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.